
Amedisys (AMED) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
621.9M
Gross Profit
273.4M
43.96%
Operating Income
72.7M
11.70%
Net Income
29.1M
4.67%
EPS (Diluted)
$0.84
Balance Sheet Metrics
Total Assets
2.2B
Total Liabilities
940.5M
Shareholders Equity
1.3B
Debt to Equity
0.74
Cash Flow Metrics
Operating Cash Flow
75.5M
Free Cash Flow
66.3M
Revenue & Profitability Trend
Amedisys Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 2.3B | 2.2B | 2.2B | 2.2B | 2.1B |
Cost of Goods Sold | 1.3B | 1.2B | 1.3B | 1.2B | 1.2B |
Gross Profit | 1.0B | 990.9M | 962.8M | 980.8M | 886.2M |
Gross Margin % | 43.3% | 44.3% | 43.3% | 44.3% | 42.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | 790.1M | 780.1M | 754.1M | 711.2M | 668.3M |
Other Operating Expenses | - | - | - | -13.3M | -34.4M |
Total Operating Expenses | 790.1M | 780.1M | 754.1M | 697.9M | 633.9M |
Operating Income | 209.6M | 193.1M | 183.8M | 251.9M | 223.4M |
Operating Margin % | 8.9% | 8.6% | 8.3% | 11.4% | 10.8% |
Non-Operating Items | |||||
Interest Income | 8.1M | 3.3M | 178.0K | 49.0K | 292.0K |
Interest Expense | 30.8M | 31.3M | 22.2M | 9.5M | 11.0M |
Other Non-Operating Income | -100.7M | -125.4M | -1.5M | 37.8M | -1.9M |
Pre-tax Income | 86.2M | 39.6M | 160.2M | 280.2M | 210.8M |
Income Tax | 48.1M | 50.6M | 42.5M | 70.1M | 25.6M |
Effective Tax Rate % | 55.7% | 127.6% | 26.6% | 25.0% | 12.2% |
Net Income | 38.2M | -10.9M | 117.7M | 210.2M | 185.2M |
Net Margin % | 1.6% | -0.5% | 5.3% | 9.5% | 8.9% |
Key Metrics | |||||
EBITDA | 292.5M | 271.4M | 256.4M | 361.0M | 296.9M |
EPS (Basic) | $1.32 | $-0.30 | $3.65 | $6.41 | $5.64 |
EPS (Diluted) | $1.31 | $-0.30 | $3.63 | $6.34 | $5.52 |
Basic Shares Outstanding | 32718000 | 32599000 | 32517000 | 32642000 | 32559000 |
Diluted Shares Outstanding | 32718000 | 32599000 | 32517000 | 32642000 | 32559000 |
Income Statement Trend
Amedisys Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 303.2M | 126.4M | 40.5M | 42.7M | 81.8M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 296.1M | 313.4M | 296.8M | 275.0M | 255.1M |
Inventory | - | - | - | - | - |
Other Current Assets | 7.7M | 8.3M | 6.4M | 5.6M | 4.5M |
Total Current Assets | 632.1M | 496.9M | 389.0M | 356.7M | 362.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 167.8M | 285.2M | 235.8M | 117.7M | 111.6M |
Goodwill | 2.5B | 2.6B | 2.7B | 2.5B | 1.9B |
Intangible Assets | 81.2M | 102.7M | 101.2M | 111.2M | 74.2M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 15.5M | 16.3M | 17.1M | 17.9M | 65.0M |
Total Non-Current Assets | 1.5B | 1.6B | 1.6B | 1.5B | 1.2B |
Total Assets | 2.1B | 2.1B | 2.0B | 1.9B | 1.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 40.0M | 28.2M | 43.7M | 38.2M | 42.7M |
Short-term Debt | 63.9M | 62.6M | 49.0M | 44.2M | 40.5M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 106.0M | 102.2M | -9.0M | -3.4M | -3.3M |
Total Current Liabilities | 514.4M | 473.7M | 355.5M | 374.3M | 456.3M |
Non-Current Liabilities | |||||
Long-term Debt | 395.4M | 424.6M | 488.9M | 501.4M | 266.5M |
Deferred Tax Liabilities | 48.1M | 40.6M | 20.4M | 0 | 27.7M |
Other Non-Current Liabilities | 182.0K | 818.0K | 4.2M | 4.0M | 4.9M |
Total Non-Current Liabilities | 444.4M | 466.7M | 514.1M | 506.4M | 300.1M |
Total Liabilities | 958.7M | 940.4M | 869.7M | 880.6M | 756.5M |
Equity | |||||
Common Stock | 38.0K | 38.0K | 38.0K | 38.0K | 38.0K |
Retained Earnings | 791.2M | 747.9M | 757.7M | 639.1M | 430.0M |
Treasury Stock | 474.9M | 468.6M | 461.2M | 435.9M | 319.1M |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.2B | 1.1B | 1.1B | 976.3M | 810.7M |
Key Metrics | |||||
Total Debt | 459.3M | 487.2M | 537.9M | 545.6M | 307.0M |
Working Capital | 117.7M | 23.2M | 33.4M | -17.6M | -94.4M |
Balance Sheet Composition
Amedisys Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 38.2M | -10.9M | 117.7M | 210.2M | 185.2M |
Depreciation & Amortization | 60.5M | 57.8M | 71.0M | 71.3M | 67.9M |
Stock-Based Compensation | 30.6M | 29.0M | 16.6M | 23.8M | 26.7M |
Working Capital Changes | 6.8M | -86.9M | -65.7M | -104.1M | 10.6M |
Operating Cash Flow | 144.5M | 116.7M | 163.9M | 246.6M | 264.8M |
Investing Activities | |||||
Capital Expenditures | -6.6M | -5.5M | -6.1M | -6.2M | -5.3M |
Acquisitions | -1.0M | 47.4M | -72.6M | -270.2M | -281.1M |
Investment Purchases | 0 | 0 | -15.0M | -5.0M | -875.0K |
Investment Sales | 0 | 150.0K | 0 | 0 | - |
Investing Cash Flow | -7.5M | 42.2M | -93.4M | -281.2M | -287.1M |
Financing Activities | |||||
Share Repurchases | -6.2M | -6.5M | -25.3M | -116.8M | -54.5M |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 23.0M | 534.5M | 791.0M | 684.2M |
Debt Repayment | 0 | -23.0M | -534.5M | -551.7M | -703.2M |
Financing Cash Flow | -49.2M | -90.2M | -36.6M | -1.9M | -43.9M |
Free Cash Flow | 214.3M | 124.5M | 126.1M | 182.2M | 283.6M |
Net Change in Cash | 87.7M | 68.6M | 33.9M | -36.4M | -66.2M |
Cash Flow Trend
Amedisys Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
39.30
Forward P/E
19.76
Price to Book
2.69
Price to Sales
1.38
PEG Ratio
-2.78
Profitability Ratios
Profit Margin
3.56%
Operating Margin
11.70%
Return on Equity
6.67%
Return on Assets
6.52%
Financial Health
Current Ratio
1.36
Debt to Equity
35.34
Beta
0.90
Per Share Data
EPS (TTM)
$2.57
Book Value per Share
$37.48
Revenue per Share
$73.28
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
amed | 3.3B | 39.30 | 2.69 | 6.67% | 3.56% | 35.34 |
HCA Healthcare | 100.9B | 18.04 | -81.93 | 13,631.68% | 8.21% | -37.45 |
Encompass Health | 12.6B | 24.02 | 5.45 | 24.72% | 9.22% | 86.97 |
Ensign Group | 10.1B | 31.83 | 4.98 | 17.54% | 7.00% | 100.93 |
DaVita | 9.4B | 12.92 | 6.41 | 57.94% | 6.35% | 825.19 |
Chemed | 6.8B | 22.80 | 5.37 | 24.14% | 11.56% | 12.15 |
Financial data is updated regularly. All figures are in the company's reporting currency.